Lipocine is trading 10.71% down at $1.50 on October 16, 2026, amid weakness across biotechnology stocks; no confirmed company-specific announcement explaining the decline has surfaced.
- The biotech ETF XBI is down 2.06%.
- Broader market coverage also describes pressure from inflation and AI-related concerns.